Sensydia Corporation announces that it has complete a Series B financing. The financing was led by Colle Capital and included all Series A investors. The funds will be used to achieve FDA approval for its revolutionary wearable Cardiac Performance System for measuring Ejection Fraction, and to develop the machine learning analytics for other important heart conditions.
Comments